Anúncio
Anúncio

PLX

PLX logo

Protalix BioTherapeutics, Inc. Common Stock

1.78
USD
Patrocinado
+0.01
+0.73%
07 de jan., 16:00 UTC -5
Encerrado
exchange

Pós-Mercado

1.75

-0.03
-1.57%

Relatórios de Lucros PLX

Rácio de surpresa positiva

PLX separação 19 de 38 últimas estimativas.

50%

Próximo Relatório

Data do Próximo Relatório
16 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$16.97M
/
$0.03
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-4.93%
/
--
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-6.84%
/
-66.67%

Protalix BioTherapeutics, Inc. Common Stock earnings per share and revenue

On 13 de nov. de 2025, PLX reported earnings of 0.03 USD per share (EPS) for Q3 25, missing the estimate of 0.05 USD, resulting in a -46.04% surprise. Revenue reached 17.85 milhão, compared to an expected 18.04 milhão, with a -1.07% difference. The market reacted with a -9.81% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analistas forecast an EPS of 0.03 USD, with revenue projected to reach 16.97 milhão USD, implying an aumentar of 0.00% EPS, and diminuir of -4.93% in Revenue from the last quarter.
FAQ
For Q3 2025, Protalix BioTherapeutics, Inc. Common Stock reported EPS of $0.03, missing estimates by -46.04%, and revenue of $17.85M, -1.07% below expectations.
The stock price moved down -9.81%, changed from $2.14 before the earnings release to $1.93 the day after.
The next earning report is scheduled for 16 de mar. de 2026.
Based on 3 analistas, Protalix BioTherapeutics, Inc. Common Stock is expected to report EPS of $0.03 and revenue of $16.97M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio